EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications

Akihiro Iguchi, Tokito Yamaguchi, Yu Tsuyusaki, Hideyuki Otani, Satoshi Mizutani, Mitsuhiro Miyashita, Manami Yabe, Katsumi Imai

Epilepsy & Behavior · 2026-08 · 181 · 111070

DOI: 10.1016/j.yebeh.2026.111070 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsy & Behavior, 2026-08. Verfasst von Akihiro Iguchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan; Department of Ped…. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Fenfluramine, Anticonvulsants. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Government of Japan Ministry of Health Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the optimal initial dose, efficacy, and adverse events of fenfluramine (FFA) in the treatment of intractable epilepsy in Dravet syndrome (DS) in Japanese patients. METHODS: This single-center, observational study included Dravet patients treated with FFA. Information retrospectively collected from medical records included age, sex, concomitant antiseizure medications (including stiripentol [STP]), the initial and maximum dose of FFA, differences in the effects of FFA with and without STP, convulsive seizure frequency, adverse events, and FFA blood concentration. RESULTS: Of the 27 patients, 13 (48.1%) were male, and the median age was 14.9 years. After the initiation of FFA, 59.3% and 25.9% of patients were 50% and 90% responders, respectively. Of the sixteen 50% responders, 13 (81.3%) had either discontinued a concomitant antiseizure medication or were in the process of reducing the dose. In 88.9% of patients, the initial dose of FFA was less than 0.2 mg/kg/day, and ≥ 50% seizure reduction was achieved in 45.8% at less than 0.2 mg/kg/day. The effectiveness of FFA was not significantly different with or without STP. Among the ≥ 50% responders, cognitive and behavioral function improved in 9 (56.3%). The major adverse events were diarrhea (29.6%). No patients developed valvular heart disease or pulmonary artery hypertension. Among patients whose blood concentrations of FFA were measured, all 50% responders had < 80 ng/mL. SIGNIFICANCE: FFA effectively reduced convulsive seizures in DS even at low concentrations. we recommend the initiation of low-dose FFA, which may allow dose reduction or discontinuation of concomitant antiseizure medications in FFA responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicFenfluramineAnticonvulsantsHumansMaleFemaleAdolescentChildRetrospective StudiesTreatment OutcomeDose-Response Relationship, DrugAdultYoung AdultChild, PreschoolDioxolanes

Stichwörter der Autor:innen

Convulsive seizuresDravet syndromeFenfluraminePlasma concentrationStiripentol

Substanzen

FenfluramineAnticonvulsantsDioxolanesstiripentol

Autor:innen und Institutionen

  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan; Department of Pediatrics, Asahi General Hospital, Chiba, Japan. Electronic address: igu…
  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Electronic address: tokito@shizuokamind.org.
  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Electronic address: y.tsuyu@gmail.com.
  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Electronic address: ohtani.hideyuki.kw@mail.hosp.go.jp.
  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Electronic address: mizu3to4@yahoo.co.jp.
  • Department of Pediatrics, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. Electronic address: mitunosuke1000@gmail.com.

Förderung

  • Government of Japan Ministry of Health Labour and Welfare

Zitieren

APA

Iguchi, A., Yamaguchi, T., Tsuyusaki, Y., Otani, H., Mizutani, S., Miyashita, M., Yabe, M., & Imai, K. (2026). Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications. Epilepsy & Behavior, 181, 111070. https://doi.org/10.1016/j.yebeh.2026.111070

Vancouver

Iguchi A, Yamaguchi T, Tsuyusaki Y, Otani H, Mizutani S, Miyashita M, et al. Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications. Epilepsy & Behavior. 2026;181:111070. doi:10.1016/j.yebeh.2026.111070

BibTeX
@article{Iguchi2026,
  author = {Iguchi, Akihiro and Yamaguchi, Tokito and Tsuyusaki, Yu and Otani, Hideyuki and Mizutani, Satoshi and Miyashita, Mitsuhiro and Yabe, Manami and Imai, Katsumi},
  title = {Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications},
  journal = {Epilepsy & Behavior},
  year = {2026},
  volume = {181},
  pages = {111070},
  doi = {10.1016/j.yebeh.2026.111070}
}
Kostenlos starten →